Neuroblastoma other imaging findings: Difference between revisions

Jump to navigation Jump to search
Line 18: Line 18:
  | doi = 10.1200/JCO.2008.20.5732
  | doi = 10.1200/JCO.2008.20.5732
  | pmid = 19805691
  | pmid = 19805691
}}</ref><ref>{{Cite journal
| author = [[Nadja C. Colon]] & [[Dai H. Chung]]
| title = Neuroblastoma
| journal = [[Advances in pediatrics]]
| volume = 58
| issue = 1
| pages = 297–311
| year = 2011
| month =
| doi = 10.1016/j.yapd.2011.03.011
| pmid = 21736987
}}</ref>
}}</ref>
** 18F-FDG [[PET scan]] may distinguish stage 1 and 2 neuroblastoma from other differential diagnosis.
** 18F-FDG [[PET scan]] may distinguish stage 1 and 2 neuroblastoma from other differential diagnosis.

Revision as of 14:01, 25 February 2019

Neuroblastoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neuroblastoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neuroblastoma other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neuroblastoma other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neuroblastoma other imaging findings

CDC on Neuroblastoma other imaging findings

Neuroblastoma other imaging findings in the news

Blogs on Neuroblastoma other imaging findings

Directions to Hospitals Treating Neuroblastoma

Risk calculators and risk factors for Neuroblastoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]Haytham Allaham, M.D. [3]

Overview

Other Imaging Findings

  • Nuclear medicine
    • Nuclear medicine studies used for diagnosis of neuroblastoma include fludeoxyglucose-18F positron emission tomography (18F-FDG PET) and metaiodobenzylguanidine (123I-MIBG) scintigraphy.[1][2][3]
    • 18F-FDG PET scan may distinguish stage 1 and 2 neuroblastoma from other differential diagnosis.
    • 123I-MIBG scintigraphy may distinguish stage 3 and 4 neuroblastoma from other differential diagnosis.
    • 123I-MIBG scintigraphy is superior than 18F-FDG PET scan in detecting bone marrow metastases.

References

  1. Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL (2009). "123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma". J Nucl Med. 50 (8): 1237–43. doi:10.2967/jnumed.108.060467. PMID 19617326.
  2. Denah R. Taggart, Myo M. Han, Alekist Quach, Susan Groshen, Wei Ye, Judith G. Villablanca, Hollie A. Jackson, Carina Mari Aparici, David Carlson, John Maris, Randall Hawkins & Katherine K. Matthay (2009). "Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27 (32): 5343–5349. doi:10.1200/JCO.2008.20.5732. PMID 19805691. Unknown parameter |month= ignored (help)
  3. Nadja C. Colon & Dai H. Chung (2011). "Neuroblastoma". Advances in pediatrics. 58 (1): 297–311. doi:10.1016/j.yapd.2011.03.011. PMID 21736987.


Template:WikiDoc Sources